GLPwatch

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377 · Completed

Last updated 2026-05-28

This clinical trial tested whether adding the medication Victoza® (liraglutide) to metformin helps control blood sugar better than adding other oral diabetes drugs to metformin in adults with type 2 diabetes over up to two years.

Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 1,991 people
Who can join Ages 18+ · all sexes
Timeline Started 2016-03 · est. completion 2019-08
Where 232 sites · Canada, Colombia, India, Latvia, Lebanon, Puerto Rico, Russia, Serbia, Turkey (Türkiye), United States

What this study is testing ClinicalTrials.gov NCT02730377 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.

Treatments tested

Main thing measuredTime to Inadequate Glycaemic Control
SponsorNovo Nordisk A/S
Conditions studiedDiabetes, Diabetes Mellitus, Type 2
GLP-1 drugs liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02730377 ↗